Valens GroWork Announces Receipt of Dealers License
Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”) is pleased to announce Valens Argitech Ltd. (“VAL”), a wholly owned subsidiary of the Company, has received a Dealers License pursuant to the provisions of the Controlled Drugs and Substances Act and its Regulations and will now begin operations. The issuance of the licence follows an extensive multi-year process that included application, design, construction and security clearance of key personnel.
Licensed activities will occur in VAL’s 17,000 square foot production facility located on two acres in Kelowna, British Columbia. VAL will be able to conduct research and possess, produce and package cannabis and cannabis derivatives. It can also undertake research and begin development of products for future market opportunities.
“Pursuing and achieving this Dealers Licence reinforces our strong commitment to the science and opportunities presented by this amazing plant.” said Tyler Robson, CEO of Valens GroWorks. Dr. Rob O’Brien, President and Chief Science Officer of Valens Agritech added “This is a critical milestone for Valens as it enables us to optimize our process for growing the highest quality cannabis plant material and converting this to oils and other derivatives.”
About Valens GroWorks Corp.
Valens GroWorks Corp is a CSE-listed company with an aggressive acquisition strategy in progress, financing the proposed buildout of late-stage LP applicant Royal Green Acres Manufacturing, the expansion of a third party’s fully licensed operations in Arizona, as well as providing management, consulting, testing and support services to domestic and international licensees.
The Company has two wholly-owned subsidiaries based in the Okanagan Valley of British Columbia: 1) Valens Agritech Ltd. (“VAL”) which now holds a Controlled Drugs and Substances Dealers Licence, and 2) Supra THC Services Inc. (“Supra”), a Health Canada Dealers-Licensed cannabis testing lab with an established scientific team supporting its operations, positioning to provide sector-leading analytical and proprietary services to Licensed Producers and ACMPR patients.
On behalf of the Board of Directors, VALENS GROWORKS CORP.
(signed) “Robert van Santen”
Chief Financial Officer
For further information, please contact:
Notice Regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections
contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.